Breaking Free From Suboptimal Outcomes: Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer (CSPC)

Breaking Free From Suboptimal Outcomes: Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer (CSPC) is organized by i3 Health.

Dates Available:
December 2, 2025 - December 1, 2026

Statement of Need:
Prostate cancer is the most common cancer in men in the United States, with 1 in 8 men and 1 in 6 Black men developing it in their lifetime. While mortality in Black men is 2-4 times higher compared to all other groups, overall prognosis by race is similar when patients are treated according to the same guidelines (NCCN, 2025). Despite the efficacy seen in combinations of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs), real-world treatment patterns demonstrate that 51% of patients with metastatic castration-sensitive prostate cancer (CSPC) do not receive optimal therapy with appropriate treatment intensification (Freedland et al, 2022). In order to optimize treatment outcomes, it is crucial to remain up to date on clinical trial evidence and real-world data of treatment intensification in metastatic CSPC and to tailor treatment selection and sequencing to meet patients’ individual needs. This Virtual Escape Room follows Rob, a 67-year-old man with metastatic CSPC, through his treatment journey. Join Dr. Ulka Vaishampayan, Professor of Medicine/Oncology and Co-Leader of the Translational Clinical Research Program at the University of Michigan Rogel Cancer Center, to help Rob break free from suboptimal outcomes in metastatic CSPC.

Learning Objectives:
Upon completion of this activity, participants should be able to

• Evaluate clinical trial evidence and real-world data to determine the survival benefits of treatment intensification in patients with metastatic castration-sensitive prostate cancer (CSPC) 
• Assess strategies for tailoring treatment selection and sequencing to meet the individual needs of patients with metastatic CSPC 
• Implement adverse event prevention and management strategies for patients with metastatic CSPC receiving novel hormonal therapy (NHT) + androgen deprivation therapy (ADT)